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Abstract: Patient-centred counseling is an integral part of the pharmaceutical care process. Quality in-
dicators can be valuable tools to measure the level of patients’ involvement in their personal healthcare. 
The aim of the study was to validate two quality indicators for community pharmacy care focusing on 
patient involvement. As part of the EDQM Pharmaceutical Care Quality Indicators Project (Council of 
Europe), at least 10 patients per indicator were recruited in each community pharmacy in Serbia and Po-
land. Pharmacists targeted patients aged 18-65 years starting chronic treatment (Indicator 1) and elderly 
patients with polymorbidity receiving at least five chronic treatment medicines (Indicator 2). Based on 
patients’ answers to a questionnaire, patient-pharmacist consultations took place. For Indicator 2, patients 
were also offered a medication review. In total, 66% of Serbian patients and 29% Polish patients, for In-
dicator 1, were engaged in pharmacist-patient consultations; 96% of Serbian and 84% of Polish elderly 
patients subsequently participated in medication reviews. Community pharmacists can increase patients’ 
involvement in their own pharmaceutical care, and there is a need for such services. This study defines 
a pragmatic approach to encourage/support the implementation of the pharmaceutical care philosophy 
and working methods in European community pharmacies.
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Healthcare services of high quality ought to 
be provided to an individual patient to increase the 
likelihood of desired health outcomes. Quality in-
dicators are tools used to measure and improve the 
quality of healthcare (1). There are few studies de-
scribing sets of quality indicators for community 
pharmacy care; however, these indicators have been 
developed and tested in specific national healthcare 
systems (2-4).
The European Committee on Pharmaceuticals 
and Pharmaceutical Care (CD-P-PH), coordinat-
ed by the European Directorate for the Quality of 
Medicines and HealthCare (EDQM) (Council of 
Europe), contributes to improving public health and 
access to good quality medicines and healthcare by 
developing harmonized provisions and practices for 
the rational use of medicines and promoting the im-
plementation of the pharmaceutical care (PC) phi-
losophy and working methods in Europe (5). The 
CD-P-PH’s activities in the PC domain are carried 
out with the support of one of its subordinate com-
mittees, the Committee of Experts on Quality and 
Safety Standards in Pharmaceutical Practices and 
Care (CD-P-PH/PC). In 2008, the CD-P-PH/PC com-
missioned a survey on key concepts in PC and per-
formance indicators used to evaluate the quality of 
PC/services in the Council of Europe member states 
(6). Based on the conclusions of the survey report, 
further development, testing, and implementation of 
a basic, generally applicable set of PC indicators was 
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recommended (6). Therefore, since 2008 CD-P-PH/
PC has been working on the ‘EDQM Pharmaceutical 
Care Quality Indicators Project’, aiming to design 
indicators to assess the quality of PC in Europe. In 
2011-2012 five sets of indicators were defined fo-
cusing on different PC areas (7). In 2013-2014 the 
CD-P-PH/PC, coordinated by the EDQM and with 
the support of the Quality of Pharmaceutical Care 
Indicators Working Party, carried out a multinational 
validation study.
One of the essential areas in the PC model in 
community pharmacy is patient counseling. During 
the conversation with patients, the pharmacist can 
determine what they understand about drug thera-
py and what concerns they may have (8-10). For the 
pharmacist, this will lead to a translation of patient-
related needs into a problem-solving format. Review 
of medicines is an essential component of the PC pro-
cess which can minimize the number of drug-relat-
ed problems (DRPs) and resolve therapy problems. 
Medication review is particularly relevant in elderly 
patients (11-14).
Consequently, one of four PC key areas iden-
tified by the Committee of Experts CD-P-PH/PC 
focused on the measurement of the level of pa-
tient involvement in the PC process and was en-
titled Structured patient-pharmacist consultations 
(chronic therapy, poly-pharmacy, poly-morbidi-
ty) via ‘My CheckList’ (Topic Group (TG) 3). ‘My 
CheckList’ is a form where patients can write down 
their expectations, concerns, experience with the 
use of their medicines and questions to be dis-
cussed with the pharmacists. Two specific indica-
tors were included in the TG3 study, evaluating the 
following items: documented counseling provided 
by a pharmacist during patient-pharmacist consul-
tation based on ‘My CheckList’ at the start of a new 
chronic treatment (Indicator 1) and documented 
medication review in elderly patients (suffering 
from multi-morbidity and receiving polypharma-
cy) having attended a ‘My CheckList’ consultation 
(Indicator 2) (15).
Aim of the study
This paper describes TG3 activities that aimed 
to validate the quality indicators in community phar-
macy settings in two European countries and to eval-
uate the views of pharmacists about the usefulness 
of the indicators.
Ethics approval
The local ethical committees approved the 
study, and the studies were performed in accordance 
with the Declaration of Helsinki.
Methods
Study settings
Prospective pilot studies were performed during 
2013-2014 in community pharmacies located in both 
urban and rural areas of Poland and Serbia.
The pilot studies were managed by a TG leader 
and carried out by national coordinators who orga-
nized and managed research activities at the local 
level. Study materials, including instructions, let-
ters for pharmacists and patients, and data collec-
tion forms for pharmacists and patients, originally 
prepared in English as provided by the TG leader 
(15), were translated into Polish and Serbian. The 
translation of the completed forms into English was 
likewise conducted.
Quality indicators testing
In Serbia, the invitation to participate in the 
study was announced on the website and in the offi-
cial journal of the Pharmaceutical Chamber of Serbia. 
In Poland, pharmacists were recruited via face-to-
face contacts and via mailings and letters to regis-
tered pharmacists. Community pharmacists volun-
tarily agreed to join the study and confirmed their 
participation by signing an agreement form.
Patients were informed about the purpose of 
the study, and their participation was voluntary 
and free of charge. Inclusion criteria for patients in 
Indicator 1 validation were: 18-65 years, and having 
been prescribed for the first time during the previ-
ous 12 months medication for chronic use (duration 
of therapy: minimum 6 months) that belongs to one 
of the following group of drugs: cardiovascular, ali-
mentary tract and metabolism, musculoskeletal, re-
spiratory system. Inclusion criteria for patients in 
Indicator 2 validation were: ≥65 years, suffering from 
multi-morbidity, and hence, being prescribed at least 
five medications for chronic conditions belonging to 
the previously mentioned groups of drugs. Overall, 
patients not eligible for enrolment in the study were 
those with whom the pharmacist could not make per-
sonal contact, physically frail elderly patients, pa-
tients receiving palliative care, and those with cog-
nitive impairment.
At the first dispensing of a newly prescribed 
medicine (Indicator 1) or when medicines for long-
term treatment were dispensed (Indicator 2), patients 
were invited to participate in the study and, if they 
agreed, they received one ‘My CheckList’ form. They 
were asked to fill in the form at home, and bring it 
to a scheduled consultation (within 2-4 weeks) with 
the pharmacist. After the consultation, based on the 
patient’s answers in ‘My CheckList’ and the patient-
pharmacist discussion, the pharmacist was expected 
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Table 1. Pharmacists’ assessment of the outcomes of the patient-pharmacist consultation.
Answer
Percent of answers
Indicator 1 Indicator 2
Serbia (N = 845) Poland (N = 21) Serbia (N = 1043) Poland (N = 36)
1. Patient better understood the use of the 
prescribed drugs 51.1 38.1 39.0 36.1
2. Identification of the potential side effects 16.7 23.8 14.8 16.7
3. Identification of non-adherence to the 
therapy 9.2 4.8 11.1 5.6
4. Patient referred to the general practitioner 
because of side effects 4.9 - 8.5 5.6
5. Patient referred to the general practitioner 
because of non-adherence 2.1 4.8 5.3 2.8
6. Other 11.8 28.6 16.8 30.6
7. No major outcome 0.2 - 1.8 2.8
8. Do not know 0.5 - 0.1 -
9. Not filled in 3.4 - 2.6 -
to summarise the main aspects and the outcomes of 
the consultation in the ‘Consultation form for phar-
macist’. Moreover, for Indicator 2, at the end of the 
patient-pharmacist consultation, if necessary, a medi-
cation review consultation was offered to the patients. 
The medication review was performed in line with the 
template proposed by the TG leader and focused on 
all medications that the patient used (prescription and 
non-prescription medicines). During the medication 
review process, the pharmacist, in cooperation with 
the patient, was asked to identify the person in charge 
of resolving/taking care of the identified issues and, 
whenever applicable, state whether the proposed ac-
tions were accepted or not by the identified person. At 
the end of the study, pharmacists were asked to com-
plete a ‘Questionnaire for pharmacists’ aimed at col-
lecting general information regarding the pharmacy 
and their views about the indicators under evaluation.
Data analysis
All data were collected anonymously. 
Measurements for assessing patients’ participation 
in the PC process were calculated as follows:
Indicator 1: a) Number of documented patient 
counseling recommendations compared to the total 
number of patients receiving ‘My CheckList’.
b) Number of documented counseling recom-
mendations during ’My Check-List’ consultation 
with at least one positive outcome (based on phar-
macist’s assessment) compared to the total number 
of patients receiving ‘My CheckList’ (for Indicator 1) 
(this additional calculation was performed to ensure 
that only fruitful consultations were actually consid-
ered for the Indicator 1 calculation).
Indicator 2: Number of documented medication 
reviews for patients having attended a consultation 
with a pharmacist compared to the total number of 
patients who attended a ‘My CheckList’ consulta-
tion (for Indicator 2).
Descriptive statistics analysis was performed 
with IBM SPSS Statistics (version 22).
RESULTS
In the pilot study conducted in Serbia, 70 phar-
macies agreed to participate in the study and 64 of 
these (response rate: 91.4%) returned the completed 
data collection forms, while in Poland response rate 
was 22.7% (5 out of 22). The majority of the par-
ticipating pharmacies were located in cities with 
a population of over 150.000 inhabitants. In total, 
30% of the community pharmacies participating 
in this study were located in towns with a popula-
tion of 150.000-1.000.000, 25% in cities with more 
than 1.000.000 inhabitants, 23% in towns between 
50.000-150.000, whereas 18% were located in small-
er towns (10.000-50.000) and only 4% in towns with 
less than 10.000 people. Around 75% of the par-
ticipating community pharmacies serve a popula-
tion below 7.000 patients: 16% have 5.000-7.000 pa-
tients, 42% have between 3.000-5.000 patients, and 
19% serve less than 3.000 patients. In total 14% of 
the recruited community pharmacies had 12.000-
15.000 patients, whereas 9.000-12.000 and more 
than 15.000 patients represented 5% of the remaining 
participating pharmacies. Only 30% of the commu-
nity pharmacies stated to have a separate consulta-
tion room, and the average number of staff members 
KATARINA M. VUČIĆEVIĆ et al.440
was 5.95+/-3.66 (median 5). Due to the differences in 
the number of pharmacies involved in the project be-
tween the two countries, and the rather small sample 
size in Poland, statistics were performed separately 
for each country, and comparisons between countries 
were deemed not to be appropriate. Detailed analyses 
of patients’ answers are included in the final report of 
the EDQM Pharmaceutical Care Quality Indicators 
Project (15), while this manuscript only focuses on 
the calculation of the 2 indicators under evaluation 
and the overall feedback received from pharmacists 
in this respect.
Indicator 1
In Serbia, 826 ‘My CheckList’ forms were pro-
vided to patients and 542 patient-pharmacist consul-
tations took place (66%). In Poland, 10 patients (out 
of 34) were involved in a consultation with their phar-
macist (29%), as given in Figure 1.
Pharmacists’ assessments of the outcome(s) of 
the patient-pharmacist consultation are summarised 
in Table 1.
The approximately same number of documented 
counseling recommendations had at least one positive 
outcome compared to the total number of patients 
receiving ‘My CheckList’: 92% and 90% for Serbia 
and Poland, respectively (Figure 1).
Indicator 2
In Serbia 549 ‘My CheckList’ forms were hand-
ed out to patients with multi-morbid chronic condi-
tions and 529 of these patients were involved in the 
medication review process (96%), whereas in Poland 
19 forms were handed out and 16 medication reviews 
were performed (84%).
Various DRPs were identified during the med-
ication review process (1144 in Serbia and 15 in 
Poland) including 14.9% and 16.7% drug-drug inter-
actions, 14.3% and 5.6% inappropriate drugs, 13.6% 
and 22.2% adverse drug reactions, 13.5% and 11.1% 
inappropriate dose and/or dosing interval, 11.4% 
and 11.1% additional therapy needed in Serbia and 
Poland, respectively (all other answers accounted for 
<10%). In total, 1241 and 18 actions were proposed 
by Serbian and Polish pharmacists, respectively, with 
a view to resolving the DRPs identified during the 
medication reviews (examples of proposed actions: 
regimen adjustment, drug change, medical exami-
nation). Pharmacists assumed that 28.6% (Serbia) or 
46.4% (Poland) of DRPs could be resolved with pa-
tients’ involvement. In both countries, the person in 
charge of considering the identified issues accepted 
the majority of the proposed actions (Serbia: 67.1%; 
Poland: 83.3%).
Pharmacists’ feedback
Overall, 87.5% and 100% of community phar-
macists in Serbia and Poland, respectively, found 
‘My CheckList’ useful in everyday practice, main-
ly in the case of polypharmacy patients receiving 
chronic treatment.
DISCUSSION
Two-way communication between patient and 
pharmacist is vital to the idea of patient-centered 
care and patient participation in the healthcare pro-
cess, as patients are expected to ask questions, talk 
to the pharmacist and understand their condition 
and therapy. This pilot study was part of the EDQM 
Pharmaceutical Care Indicators Project.
As the main barrier to effective communica-
tion is time available for pharmacists to spend with 
patients, the model we have used in our study seems 
appropriate as almost all community pharmacists 
who participated in the research project found the 
approach useful for their daily practice. It splits 
the PC consultation process into two or potentially 
three meetings, and it gives patients enough time to 
contemplate and formulate the issues they are most 
concerned about and include information they re-









Figure 1. Total number of patients receiving ‘My CheckList’ (sum of dark and light grey), number of documented patient-pharmacist 
consultations (light grey), and number of documented counseling recommendations with at least one positive outcome (shaded) after pilot 
testing of Indicator 1 in a) the Republic of Serbia, b) Poland.
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time, during the consultation process, the phar-
macist can better understand a patient’s worries, 
potential issues, and DRPs from the form and the 
counseling is going to be more effective, focused 
on problem-solving, and directed towards the pa-
tient’s needs.
Patient involvement and participation in PC 
can be challenging, but it is essential as it facilitates 
the achievement of meaningful and effective thera-
peutic outcomes (16). Based on our results, a large 
percentage of patients attending Serbian community 
pharmacies were willing to become more involved 
in their therapy management. On the contrary, in 
Poland the response rate was lower, indicating that 
engaging patients could be more delicate and diffi-
cult here. Such results might be attributable to the 
fact that relatively few patients were approached due 
to the heavy workload in community pharmacies, as 
the current daily practice does not include PC ser-
vices. Moreover, patients who were enrolled in the 
study, perhaps, did not completely understand the 
benefit of the form and the consultation with their 
pharmacist. Therefore, it can be concluded that, in 
order to facilitate effective patient participation in 
the PC process, patients need to understand the pur-
pose and added value of the partnership with their 
pharmacists, as well as their role in achieving bet-
ter therapy outcomes, as previously mentioned (17). 
Additionally, it goes without saying that good com-
munication and interpersonal skills during the con-
sultation are required to establish positive healthcare 
professional-patient relationships and deliver high-
quality patient-centered care (18).
Targeting patients who are going to benefit the 
most from the service seems to be another impor-
tant issue. Patients’ acknowledgment of their chronic 
disease may be associated with difficulties in adjust-
ing to the limitations that the condition imposes on 
their everyday life. Introducing a new medicine for 
long-term treatment can be delicate, as a patient has 
to decide whether he is going to take the prescribed 
medicine(s). Likewise, elderly patients with multi-
morbidity on chronic polypharmacy often require 
specific attention to make certain that the treatment 
goals are being met. Therefore, the indicators un-
der consideration successfully responded to the pa-
tients’ needs and contributed to the responsible and 
safe use of medicines in such populations, as previ-
ously published (8-10). In addition, it is evident that 
‘My CheckList’ was discrete enough to provide in-
formation for the evaluation of actual and potential 
DRPs that would lead to targeted interventions by 
pharmacists. Furthermore, almost all pharmacists 
involved in this study indicated that the outcome of 
the consultation was positive for the patient (Table 1). 
This is indicative of the quality of the PC service in 
our study.
Active patient participation is required for the 
medication review (17, 19). In this study, an assess-
ment of the patients’ pharmacotherapy was per-
formed for a large percentage of elderly patients af-
ter the initial consultation with the pharmacist. This 
indicates that patients perceived the importance and 
the value of the initial conversation with their phar-
macist. This highlights the importance of the pa-
tient’s positive experience during the first contact 
with the pharmacist. Therefore, patient follow-up 
should be considered in a systematic manner, as PC 
is a continuous cycle of needs assessment, care plan-
ning, and interventions to resolve DRPs.
With respect to the medication review process, 
it is interesting to note that the results of this study 
indicate that several DRPs were identified in phar-
macist-conducted medication reviews and that the 
overall acceptance of the actions proposed to resolve 
these DRPs was high (67.1% and 83.3% acceptance 
in Serbia and in Poland, respectively). These out-
comes provide further support for the hypothesis 
that medication reviews are an effective tool for the 
identification of drug-related problems and can play 
an important role in improving the quality and safe-
ty of the medication process. Finally, while substan-
tially larger studies would be required to confirm the 
long-term positive clinical and economic benefits of 
pharmacist-led medication reviews, our findings sug-
gest a need for greater integration of this service into 
primary care provision (20-22).
Despite these promising results, the general-
isability of the study outcomes is subject to certain 
limitations. First, given the limited number of coun-
tries involved in our study, and the small sample 
size in one of them (which was a limitation in per-
forming a statistical analysis to test differences in 
observations between two countries), the validity of 
the indicators under evaluation could not be fully 
evaluated. Second, there was an open call to recruit 
study participants; as a consequence, it could be ar-
gued that more motivated pharmacists and patients 
agreed to join the research project, and therefore, 
recruitment bias cannot be ruled out. Third, stud-
ies and several reviews conducted on the subject 
have shown that successful patient-centered care re-
quires the collaboration of patients and their health-
care providers (23-25). The fact that our study did 
not involve collaboration between pharmacists and 
other members of the healthcare team means that 
only a partial contribution to the provision of com-
prehensive and in-depth patient care was possible. 
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Finally, it is important to bear in mind that no pa-
tient follow-up was carried out after the pharma-
cists’ interventions.
Notwithstanding the above limitations, the re-
sults of this study define a pragmatic approach to 
encourage and support the implementation of the 
PC philosophy and working methods in commu-
nity pharmacy settings in Europe. Consequently, 
Indicators 1 and 2 can be implemented and used by 
national policy-makers and healthcare professionals 
to assess the quality of specific PC activities and poli-
cies, as they seem to be practical and straightforward 
to use in daily practice.
Finally, it is important to bear in mind that the 
implementation of the PC philosophy and the use 
of quality indicators in community pharmacy prac-
tice in European countries might not be straightfor-
ward and instantaneous; it requires time, political 
will, support, and collaboration with the prescribers 
and other key stakeholders involved in the medica-
tion management process. Nevertheless, in Serbia, 
new legislation focusing on good pharmacy prac-
tice in community and hospital pharmacy settings 
was adopted and came into effect from 1st April 
2021 (26). The above legislation is in compliance 
with the appropriate guidelines of the International 
Pharmaceutical Federation (FIP) and World Health 
Organization (WHO), including standards of PC 
services. Among others, counseling and medication 
review services are the core of this country-specific 
legislation. We are confident that this study, together 
with other professional and research activities, con-
tributed to the overall position of PC standards in 
good pharmacy practice. In Poland, the pharmacist 
may provide PC service as supported by Polish law 
for a long time (including the period when this re-
search has been performed) (27). Since December 
2020, the act on the pharmacist profession describes 
in detail what PC is. This act lists the activities per-
formed by a pharmacist: pharmaceutical consulta-
tions, medication reviews, developing an individual 
PC plan, performing diagnostic tests, and issuing 
prescriptions as part of the continuation of a medi-
cal order (27). However, these services are not pro-
vided in pharmacies regularly yet. At that time, 
Polish law allowed a pharmacist to provide phar-
maceutical care.
CONCLUSIONS
The outcomes of our research substantiated the 
hypothesis that our indicators have the potential to 
play a considerable role in the involvement of spe-
cific patient groups in the PC process in community 
pharmacies. This information can be used to en-
courage their implementation in daily practice with 
a view to achieving the best medication outcomes 
for patients. The importance of the study lies in the 
fact that, among other documents, the conclusions 
and recommendations of the EDQM Pharmaceutical 
Care Quality Indicators Project were considered and 
taken into account in the drafting process of Council 
of Europe Resolution CM/Res(2020)3 on the imple-
mentation of pharmaceutical care for the benefit of 
patients and health services, which was adopted by 
the Council of Europe Committee of Ministers in 
March 2020 (28).
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